What are the challenges associated with CAR T-cell therapy in patients with AML?

During the 6th European CAR T-Cell Meeting, the AML Hub spoke to Sarah Tettamanti, Tettamanti Foundation Research Center, Monza, IT. We asked, What are the challenges associated with chimeric antigen receptor T-cell therapy in patients with acute myeloid leukemia (AML)?
Firstly, Tettamanti discusses some of the challenges in developing chimeric antigen receptor T-cell therapies for the treatment of patients with AML, such as identification of suitable target tumor-associated antigens, potential off-target toxicities, and lack of persistence resulting in relapse. She then highlights how the disease biology of AML and prior treatment can hinder the manufacturing process, and concludes by discussing novel strategies to overcome these challenges.